2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Diseases
2
Lung Non-Squamous Non-Small Cell Carcinoma
1
Lung Neoplasms
1
Carcinoma
1
Interventions
Carboplatin
19
Pemetrexed
10
Paclitaxel
7
pembrolizumab
5
Nivolumab
5
Cisplatin
5
Gemcitabine
4
osimertinib
3
entinostat
3
camrelizumab
3
atezolizumab
3
Erlotinib Hydrochloride
3
Bronchoscopy
3
zipalertinib
2
selpercatinib
2
pralsetinib
2
durvalumab
2
apatinib
2
Vinorelbine
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Drug Delivery Systems
2
Docetaxel
2
Blood Specimen Collection
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
toripalimab
1
taletrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lung Diseases
×
zipalertinib
×
Clear all
NCT05967689
2026-05-28
REZILIENT2
Taiho Oncology, Inc.
Phase 2
Recruiting
220 enrolled
NCT05973773
2026-05-28
REZILIENT3
Taiho Oncology, Inc.
Phase 3
Active not recruiting
285 enrolled